Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity indexes during one year infliximab therapy in pediatric patients with Crohn's disease

Dolóresz Szabó, Gyöngyi Kökönyei, A. Arató, Antal Dezsofi, Kriszta Molnár, Katalin Eszter Müller, P. Lakatos, M. Papp, Barbara D. Lovász, Petra A. Golovics, Áron Cseh, G. Verès

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Quality of life (QoL) is an important outcome measure in the evaluation of therapies for inflammatory bowel disease. The primary aim of this study was to determine the effect of one year infliximab treatment on QoL and clinical parameters in pediatric patients with Crohn's diseases (CD). Methods: Our prospective study involved 51 children with conventional therapy resistant, severe CD (mean age: 15.25. years, range: 11-18. years). Infliximab was given according to the protocol (5. mg/kg, at weeks 0, 2, 6 and every 8. weeks). During the infliximab courses QoL of patients was evaluated by IMPACT-III questionnaire at weeks 0, 6, 30 and 53. At the same time, the Pediatric Crohn's Disease Activity Index (PCDAI) score was calculated. Moreover, serum C-reactive protein (CRP), serum platelets and serum albumin were followed up. Auto-regressive, cross-lagged models were used to assess relation between QoL and the clinical parameters. Results: The initial IMPACT-III scores [median, percentile 25-75 (pc 25-75) at week 0: 115, 102.5-130.25] increased significantly (p <0.001) following infliximab therapy at week 54 (median: 141.5, 124.5-153.75). Clinical and laboratory parameters also improved significantly (p <0.001). Auto-regressive regression coefficients (β value) were significant between each variable over time. The strongest cross-lagged relations were observed between IMPACT-III and serum albumin, IMPACT-III and platelets. Reliability test of IMPACT-III revealed an excellent level of internal consistency (Cronbach's alpha = 0.931). Conclusion: Infliximab treatment has beneficial clinical effect which is confirmed by decrease of PCDAI and increase of IMPACT-III. Autoregressive regression analysis showed regression relation between IMPACT-III and PCDAI and laboratory parameters.

Original languageEnglish
Pages (from-to)747-755
Number of pages9
JournalJournal of Crohn's and Colitis
Volume8
Issue number8
DOIs
Publication statusPublished - Aug 1 2014

Fingerprint

Crohn Disease
Pediatrics
Quality of Life
Serum Albumin
Blood Platelets
Therapeutics
Inflammatory Bowel Diseases
C-Reactive Protein
Blood Proteins
Regression Analysis
Outcome Assessment (Health Care)
Infliximab
Pediatric Crohn's disease
Prospective Studies
Serum

Keywords

  • Autoregressive cross-lagged analysis
  • Crohn's disease
  • IMPACT-III
  • Infliximab
  • Pediatric

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity indexes during one year infliximab therapy in pediatric patients with Crohn's disease. / Szabó, Dolóresz; Kökönyei, Gyöngyi; Arató, A.; Dezsofi, Antal; Molnár, Kriszta; Müller, Katalin Eszter; Lakatos, P.; Papp, M.; Lovász, Barbara D.; Golovics, Petra A.; Cseh, Áron; Verès, G.

In: Journal of Crohn's and Colitis, Vol. 8, No. 8, 01.08.2014, p. 747-755.

Research output: Contribution to journalArticle

Szabó, Dolóresz ; Kökönyei, Gyöngyi ; Arató, A. ; Dezsofi, Antal ; Molnár, Kriszta ; Müller, Katalin Eszter ; Lakatos, P. ; Papp, M. ; Lovász, Barbara D. ; Golovics, Petra A. ; Cseh, Áron ; Verès, G. / Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity indexes during one year infliximab therapy in pediatric patients with Crohn's disease. In: Journal of Crohn's and Colitis. 2014 ; Vol. 8, No. 8. pp. 747-755.
@article{d7767963c4594a6198d8dcb41b0dcda0,
title = "Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity indexes during one year infliximab therapy in pediatric patients with Crohn's disease",
abstract = "Background: Quality of life (QoL) is an important outcome measure in the evaluation of therapies for inflammatory bowel disease. The primary aim of this study was to determine the effect of one year infliximab treatment on QoL and clinical parameters in pediatric patients with Crohn's diseases (CD). Methods: Our prospective study involved 51 children with conventional therapy resistant, severe CD (mean age: 15.25. years, range: 11-18. years). Infliximab was given according to the protocol (5. mg/kg, at weeks 0, 2, 6 and every 8. weeks). During the infliximab courses QoL of patients was evaluated by IMPACT-III questionnaire at weeks 0, 6, 30 and 53. At the same time, the Pediatric Crohn's Disease Activity Index (PCDAI) score was calculated. Moreover, serum C-reactive protein (CRP), serum platelets and serum albumin were followed up. Auto-regressive, cross-lagged models were used to assess relation between QoL and the clinical parameters. Results: The initial IMPACT-III scores [median, percentile 25-75 (pc 25-75) at week 0: 115, 102.5-130.25] increased significantly (p <0.001) following infliximab therapy at week 54 (median: 141.5, 124.5-153.75). Clinical and laboratory parameters also improved significantly (p <0.001). Auto-regressive regression coefficients (β value) were significant between each variable over time. The strongest cross-lagged relations were observed between IMPACT-III and serum albumin, IMPACT-III and platelets. Reliability test of IMPACT-III revealed an excellent level of internal consistency (Cronbach's alpha = 0.931). Conclusion: Infliximab treatment has beneficial clinical effect which is confirmed by decrease of PCDAI and increase of IMPACT-III. Autoregressive regression analysis showed regression relation between IMPACT-III and PCDAI and laboratory parameters.",
keywords = "Autoregressive cross-lagged analysis, Crohn's disease, IMPACT-III, Infliximab, Pediatric",
author = "Dol{\'o}resz Szab{\'o} and Gy{\"o}ngyi K{\"o}k{\"o}nyei and A. Arat{\'o} and Antal Dezsofi and Kriszta Moln{\'a}r and M{\"u}ller, {Katalin Eszter} and P. Lakatos and M. Papp and Lov{\'a}sz, {Barbara D.} and Golovics, {Petra A.} and {\'A}ron Cseh and G. Ver{\`e}s",
year = "2014",
month = "8",
day = "1",
doi = "10.1016/j.crohns.2013.12.020",
language = "English",
volume = "8",
pages = "747--755",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity indexes during one year infliximab therapy in pediatric patients with Crohn's disease

AU - Szabó, Dolóresz

AU - Kökönyei, Gyöngyi

AU - Arató, A.

AU - Dezsofi, Antal

AU - Molnár, Kriszta

AU - Müller, Katalin Eszter

AU - Lakatos, P.

AU - Papp, M.

AU - Lovász, Barbara D.

AU - Golovics, Petra A.

AU - Cseh, Áron

AU - Verès, G.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Background: Quality of life (QoL) is an important outcome measure in the evaluation of therapies for inflammatory bowel disease. The primary aim of this study was to determine the effect of one year infliximab treatment on QoL and clinical parameters in pediatric patients with Crohn's diseases (CD). Methods: Our prospective study involved 51 children with conventional therapy resistant, severe CD (mean age: 15.25. years, range: 11-18. years). Infliximab was given according to the protocol (5. mg/kg, at weeks 0, 2, 6 and every 8. weeks). During the infliximab courses QoL of patients was evaluated by IMPACT-III questionnaire at weeks 0, 6, 30 and 53. At the same time, the Pediatric Crohn's Disease Activity Index (PCDAI) score was calculated. Moreover, serum C-reactive protein (CRP), serum platelets and serum albumin were followed up. Auto-regressive, cross-lagged models were used to assess relation between QoL and the clinical parameters. Results: The initial IMPACT-III scores [median, percentile 25-75 (pc 25-75) at week 0: 115, 102.5-130.25] increased significantly (p <0.001) following infliximab therapy at week 54 (median: 141.5, 124.5-153.75). Clinical and laboratory parameters also improved significantly (p <0.001). Auto-regressive regression coefficients (β value) were significant between each variable over time. The strongest cross-lagged relations were observed between IMPACT-III and serum albumin, IMPACT-III and platelets. Reliability test of IMPACT-III revealed an excellent level of internal consistency (Cronbach's alpha = 0.931). Conclusion: Infliximab treatment has beneficial clinical effect which is confirmed by decrease of PCDAI and increase of IMPACT-III. Autoregressive regression analysis showed regression relation between IMPACT-III and PCDAI and laboratory parameters.

AB - Background: Quality of life (QoL) is an important outcome measure in the evaluation of therapies for inflammatory bowel disease. The primary aim of this study was to determine the effect of one year infliximab treatment on QoL and clinical parameters in pediatric patients with Crohn's diseases (CD). Methods: Our prospective study involved 51 children with conventional therapy resistant, severe CD (mean age: 15.25. years, range: 11-18. years). Infliximab was given according to the protocol (5. mg/kg, at weeks 0, 2, 6 and every 8. weeks). During the infliximab courses QoL of patients was evaluated by IMPACT-III questionnaire at weeks 0, 6, 30 and 53. At the same time, the Pediatric Crohn's Disease Activity Index (PCDAI) score was calculated. Moreover, serum C-reactive protein (CRP), serum platelets and serum albumin were followed up. Auto-regressive, cross-lagged models were used to assess relation between QoL and the clinical parameters. Results: The initial IMPACT-III scores [median, percentile 25-75 (pc 25-75) at week 0: 115, 102.5-130.25] increased significantly (p <0.001) following infliximab therapy at week 54 (median: 141.5, 124.5-153.75). Clinical and laboratory parameters also improved significantly (p <0.001). Auto-regressive regression coefficients (β value) were significant between each variable over time. The strongest cross-lagged relations were observed between IMPACT-III and serum albumin, IMPACT-III and platelets. Reliability test of IMPACT-III revealed an excellent level of internal consistency (Cronbach's alpha = 0.931). Conclusion: Infliximab treatment has beneficial clinical effect which is confirmed by decrease of PCDAI and increase of IMPACT-III. Autoregressive regression analysis showed regression relation between IMPACT-III and PCDAI and laboratory parameters.

KW - Autoregressive cross-lagged analysis

KW - Crohn's disease

KW - IMPACT-III

KW - Infliximab

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=84904467297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904467297&partnerID=8YFLogxK

U2 - 10.1016/j.crohns.2013.12.020

DO - 10.1016/j.crohns.2013.12.020

M3 - Article

VL - 8

SP - 747

EP - 755

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 8

ER -